Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT00039455
What this trial is testing

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
National Cancer Institute (NCI) 50
Large-scale testing (Phase 3)Study completedNCT01101438
What this trial is testing

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Who this might be right for
Breast Cancer
Canadian Cancer Trials Group 3,649
Testing effectiveness (Phase 2)Looking for participantsNCT04993014
What this trial is testing

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

Who this might be right for
Breast NeoplasmsHER2-positive Breast CancerCirculating Tumor Cell
AC Camargo Cancer Center 80
Testing effectiveness (Phase 2)UnknownNCT02993198
What this trial is testing

A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging

Who this might be right for
HER2 Positive Breast CancerCardiovascular Abnormalities
Northwestern University 134
Early research (Phase 1)Study completedNCT00228358
What this trial is testing

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Who this might be right for
HER2-positive Breast CancerRecurrent Breast CancerRecurrent Non-small Cell Lung Cancer+6 more
University of Washington 8
Testing effectiveness (Phase 2)Ended earlyNCT01873833
What this trial is testing

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerRecurrent Breast CancerStage IV Breast Cancer
University of Southern California 10
Not applicableStudy completedNCT06161922
What this trial is testing

Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy

Who this might be right for
HER2-positive Breast Cancer
Fudan University 600
Early research (Phase 1)Study completedNCT03032107
What this trial is testing

Pembrolizumab In Combination With Trastuzumab-DM1

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 20
Testing effectiveness (Phase 2)Study completedNCT01105312
What this trial is testing

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 28
Testing effectiveness (Phase 2)Study completedNCT00618657
What this trial is testing

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

Who this might be right for
Breast CancerHER2-negative Breast CancerHER2-positive Breast Cancer+7 more
University of California, Irvine 127
Early research (Phase 1)Study completedNCT04487236
What this trial is testing

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsHER2-positive Breast Cancer
Suzhou Zanrong Pharma Limited 61
Testing effectiveness (Phase 2)UnknownNCT04034823
What this trial is testing

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 59
Testing effectiveness (Phase 2)UnknownNCT04094896
What this trial is testing

TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer

Who this might be right for
HER2-Positive Breast Cancer
Guangdong Provincial People's Hospital 200
Testing effectiveness (Phase 2)Looking for participantsNCT05955170
What this trial is testing

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Institut Curie 66
Early research (Phase 1)Study completedNCT03330561
What this trial is testing

PRS-343 in HER2-Positive Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more
Pieris Pharmaceuticals, Inc. 85
Post-approval studies (Phase 4)Looking for participantsNCT07695259
What this trial is testing

Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer

Who this might be right for
Elderly FemalesHER2 + Breast CancerNeoadjuvant Therapy
Wen-Ming Cao 45
Testing effectiveness (Phase 2)UnknownNCT05263869
What this trial is testing

MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Who this might be right for
Breast Cancer With Liver Metastases
Shanghai Miracogen Inc. 99
Large-scale testing (Phase 3)Looking for participantsNCT07518173
What this trial is testing

BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 596
Large-scale testing (Phase 3)Looking for participantsNCT05760612
What this trial is testing

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Who this might be right for
Early-stage Breast CancerHER2-positive Breast CancerAdjuvant Treatment After Trastuzumab+2 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Not applicableStudy completedNCT07115095
What this trial is testing

Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Nanlin Li 98
Next Page